Unlike the NFL so far, all the key players in the RNAi field got together and worked it out.
The deal between Alnylam, Max Planck Society, UMass, and the Whitehead Institute and MIT concerns the prosecutio and disposition of the Tuschl I and Tuschl II patents.
Max Planck will take the lead role in coordinating all prosecution of the Tuschl II family of patents worldwide. UMass will lead prosecution of Tuschl I patents outside the US, and will sublicense TuschI II patents to Merck with permission from Alnylam. Alnylam will receive a portion ofthe licensing fees.
Posted by Bruce Lehr March 15th 2011.